Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's sounds like DC vax if targeted to cancer...
His keynote presentation is about Tapimmune vaccine! I believe he is going over the mechanism of the vaccine.
http://www.immuno-oncologysummit.com/Personalized-Cancer-Vaccines/
Scroll down to Sept 1st. Keynote speaker Keith Knits on.
Hope for a merger...
Thanks!
This was two years ago
So quiet here...
What happened to the CEO? Is he leaving?
Rk what's the main thing that distinguishes Gale and Tpiv? Why gale failed ?
Millionaires? Daytraders would have to buy many million shares....if it runs back to $0.1 before aug, that would be awesome!!
Yep! China is a HUGEEEEE market!! Plus India and the rest!! Even though there is no FDA approval YET, I think we are still good...
I meant if Shenghuo has a website?
RK, do you know if Shenghuo'website
Bought more today around 0.0049...holding all my shares!!
This is indeed a pretty risky stock. But I think the product is awesome! Non invasive scan ! Might pick up more tomorrow ...
Thanks, Rk. Hope we see this turn before earning...??????
Rk, why are there still people buying this stock at this juncture?
Red on most of the biotech stocks today...
Hi Rk, next earning will be Sept., how likely do you think they will reverse split before earning?
So you mean we will find out if there is a r/s on Aug?
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON AUGUST 4, 2016
TO THE STOCKHOLDERS:
Notice is hereby given that the 2016 annual meeting of stockholders of Guided Therapeutics, Inc., a Delaware corporation (the “Company”), will be held on Thursday, August 4, 2016 at 10:00 a.m., local time, at the Company’s offices, located at 5835 Peachtree Corners East, Suite D, Norcross, Georgia 30092, for the following purposes:
1. to elect three directors;
2. to approve an amendment to the Company’s certificate of incorporation to effect a reverse stock split, in a ratio to be determined by the Company’s board of directors ranging from 1-for-10 to 1-for-400, of all issued and outstanding shares of the Company’s common stock, at a time in the three years following such
Is r/s coming?
Could it be break thru designation?
Wow... Anyone sees any opportunities?
Anyone knows if tpiv still keeping in touch with the 20/21 women in the phase I trial?
How does immune response translate to efficacy? I wonder how those 20 patients in Phase 1 are doing?
Think they are getting any undisclosed upfront payment??
RK...any important take away from the 8K filed?
I find your post very informative. Great stuff. I don't have much in this stock. Can you shed some more light in enum ?
RK, is this still at a good buy at this level knowing money will still be made from other countries? I just don't understand why the sp is still way low.
Why no volume today?
RK, what was the reason FDA requires more testing in LuViva?
How is the regulatory approval like for medical device thru FDA?
RK...thanks!
RK, did Tom ask you to join his groupme tpiv group?
??????
At the quarter ended November 30, 2015, CytoDyn had $3.25 million cash on hand. However, during January 2016, the company completed a private placement offering using Paulson Investment Company as the placement agent under which the company raised a total of over $20 million in cash by offering 33M shares of common stock. Included with this offering were 16,669,331 warrants with an exercise price of $0.75. The exercise of these warrants would provide the company with an additional $12.5 million in cash. With its current burn rate of roughly $1.5 million per month, the company now has sufficient cash to fund operations into mid-2017. The company’s share sale agreement with Paulson Investment Company has now concluded and the company is no longer issuing shares.
This cash raise was an extremely important development for CytoDyn Inc. given their relatively low cash position at November 30, 2015. This raise provides the company sufficient capital to fund their operations for the foreseeable future, well into 2017 at a minimum, and allows management to focus on the clinical development of their pipeline. This private placement is also quite significant as the current market environment has made it extremely difficult for companies within the biotechnology sector to raise capital. The fact that CytoDyn, a relatively unknown company that trades on the OTC, was able to raise funds through a respected investment bank in a private placement offering speaks volumes about how much potential their pipeline holds.
I am following jbem... He has a detailed dd on Google group.. Are you a subscriber of jbem?
Thanks Rk...heard of Pro140? Cytodyn....
Going into private? What would happen to our shared?